Marinus Pharmaceuticals — Investor Presentation (May 2020)
33 slides from Marinus Pharmaceuticals's investor presentation, May 4, 2020
Slide 1: Corporate Overview 2020
NASDAQ: MRNS @ MarinusPharma Corporate Overview 2020
Slide 2: Safe Harbor Statement
©2020 Marinus Pharmaceuticals. All Rights Reserved I Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management mad
Slide 3: Ganaxolone Targets Synaptic & Extrasynaptic GABA A Receptors
©2020 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone (GNX) Targets Synaptic & Extrasynaptic GABA A Receptors 3 Ganaxolone a positive allosteric GABA A modulator with a well - defined MOA designed to treat patients suffering from epilepsy and neuropsychiatric disorders. GNX is designed to
Slide 4: Ganaxolone Development Pipeline
©2020 Marinus Pharmaceuticals. All Rights Reserved I GANAXOLONE PHASE 1 PHASE 2 PHASE 3 ANTICIPATED MILESTONES Seizure Disorders Initiate mid - 2020 Data Q3 2020 Initiate 1H 2020 Data 2021 Depressive Disorders* Ganaxolone Development Pipeline Treatment Resistant Depression (TRD) Status Epilepticus (
Slide 5: Status Epilepticus Indication
Status Epilepticus Indication
Slide 6: Status Epilepticus: Definition and Epidemiology
©2020 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus (SE): Definition and Epidemiology Background • Continuous seizures lasting >5 min • Heterogenous patient population with various etiologies, including glioblastoma, vascular disease, encephalitis, drug or alcohol withdrawal or o
Slide 7: Goals of a New Therapy for the Treatment of SE
©2020 Marinus Pharmaceuticals. All Rights Reserved I Goals of a new treatment Rapid cessation Maintenance of seizure control Prevent progression to IV anesthetics Goals of a New Therapy for the Treatment of SE 7 Benzodiazepine Administered Medically induced Coma Established Status Epilepticus (ESE)
Slide 8: SE Trial Design
©2020 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper Phase 2 SE Trial Design 8 Diagnosis of convulsive or non - convulsive SE Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics Bolus plus continuous infusion 2 - 4 d
Slide 9: Baseline Characteristics
©2020 Marinus Pharmaceuticals. All Rights Reserved I Baseline Characteristics 9 Data presented at AES 2019 NCSE: Non - convulsive status epilepticus; CSE: Convulsive status epilepticus; LAC: Lacosamide ; LEV: Levetiracetam • 8 males, 9 females • Mean age: 57 years old (range: 23 - 88) • 5 (29%) CSE,
Slide 10: Phase 2 Trial Results Showed Rapid Onset, Durability of Efficacy at High Dose
©2020 Marinus Pharmaceuticals. All Rights Reserved I Phase 2 Trial Results Showed Rapid Onset, Durability of Efficacy at High Dose Cohort No escalation to IV anesthetics within 24 hrs from infusion initiation (Primary Endpoint) Status - free through 24 hrs from infusion initiation No escalation to a
Slide 11: PK/PD Relationship and Rationale for Target Dose
©2020 Marinus Pharmaceuticals. All Rights Reserved I PK/PD Relationship and Rationale for Target Dose 11 Seizure Burden Reduction Occurred Rapidly in All Dose Groups Modeled PK Curves for All Dose Groups High Dose Achieves Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduc
Slide 12: IV Ganaxolone Safety Summary
©2020 Marinus Pharmaceuticals. All Rights Reserved I IV Ganaxolone Safety Summary 12 Intubation: 9 patients were not intubated upon enrollment. Of these, 6 remained intubation - free during the entire ganaxolone treatment perio d Data presented at AES 2019 AE: adverse event / SAE: serious adverse ev
Slide 13: Phase 3 SE Plan
©2020 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 SE Plan 13 • Target dose range extends GNX exposure ≥ 500 ng/mL to 12 hours; IV bolus followed by 36 - hour infusion followed by a 12 - hour taper (48 hours in total) • SE cessation within 30 minutes, No progression to IV anesthesia for at
Slide 14: SE Phase 3 Clinical Planning: On Track for First Patient In September
©2020 Marinus Pharmaceuticals. All Rights Reserved I SE Phase 3 Clinical Planning: On Track for First Patient In September 14 • 1:1 randomized, double - blind, placebo - controlled trial • Failure of a benzodiazepine and 2 second - line IV AEDs • 3 - minute bolus, 36 - hr infusion, 12 - hr taper • A
Slide 15: CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder
Slide 16: CDKL5 Deficiency Disorder – Rare, Serious Epileptic Condition
©2020 Marinus Pharmaceuticals. All Rights Reserved I Cause Mutation of the cyclin - dependent kinase - like 5 (CDKL5) gene, located on the X chromosome Symptoms Early - onset, treatment refractory seizures, & severe neuro - developmental delay Most can’t walk, talk or care for themselves Suffer from
Slide 17: CDD Phase 2 Trial Design
©2020 Marinus Pharmaceuticals. All Rights Reserved I 26 weeks ganaxolone 600 mg 3x/day maximum 12 weeks Trial Details 2 sites in US; 1 site in Italy 6 females, 1 male – ages 2 - 16 Confirmed CDKL5 mutation, stable background treatment, >4 seizures per 28 - day period in baseline Baseline Characteris
Slide 18: Efficacy & Safety Data in Phase 2 Trial in CDD
©2020 Marinus Pharmaceuticals. All Rights Reserved I Efficacy & Safety Data in Phase 2 Trial in CDD Data presented at AES 2018 18 • Patients experienced a median ‘minimally improved’ rating on CGI - I scale (Clinician rated) correlated with % change in seizure frequency • GNX was generally safe and
Slide 19: Durable Responses Seen in CDD Phase 2 Extension
©2020 Marinus Pharmaceuticals. All Rights Reserved I Durable Responses Seen out to 18 Months in CDD Phase 2 Extension • 4 of 7 patients entered the extension period • Ganaxolone demonstrated preliminary evidence of sustained, long - term (out to 18 months) efficacy in a small cohort of CDD patients
Slide 20: Global Phase 3 Pivotal Trial Design
©2020 Marinus Pharmaceuticals. All Rights Reserved I Global Phase 3 Pivotal Trial Design 20 Baseline 6 weeks Historical Control 8 weeks Double - Blind Phase Open - Label Phase Maintenance 13 weeks Titration 4 weeks Titration 4 weeks Open - Label Phase Trial Details • Evaluate the use of oral ganaxol
Slide 21: Tuberous Sclerosis Complex
Tuberous Sclerosis Complex
Slide 22: Allo-S as Potential Biomarker Across Various Genetic Epilepsies
©2020 Marinus Pharmaceuticals. All Rights Reserved I Allo - S as Potential Biomarker Across Various Genetic Epilepsies 22 Scientific literature associates genetic orphan epilepsies with neurosteroid imbalances Marinus has identified abnormal neurosteroid levels in several patient subtypes These find
Slide 23: Tuberous Sclerosis Complex – Rare, Serious Genetic Disorder
©2020 Marinus Pharmaceuticals. All Rights Reserved I Cause Defect or mutation of TSC1 and/or TSC2 genes Symptoms Benign tumors, seizures, cognitive impairment, behavioral problems, skin abnormalities Prevalence ~25K-40K refractory TSC patients in the U.S.* Treatments Limited approved treatments Mech
Slide 24: Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone
©2020 Marinus Pharmaceuticals. All Rights Reserved I Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone • Epilepsy present in ~90% of individuals affected with TSC • Existing treatments fail to control seizures in ~60% of individuals with TSC - associated epilepsy • Uncontrolled seiz
Slide 25: TSC Phase 2 Open-Label Clinical Trial Design
©2020 Marinus Pharmaceuticals. All Rights Reserved I PART A PART B Base (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Open - Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol TSC - Phase 2 Open - Label Clinical Trial Design • n = 30 •
Slide 26: PCDH19 Related Epilepsy
PCDH19 Related Epilepsy
Slide 27: PCDH19-Related Epilepsy – Rare, Serious Epileptic Condition
©2020 Marinus Pharmaceuticals. All Rights Reserved I Cause Inherited mutation of protocadherin 19 (PCDH19) gene. Located on X chromosome Symptoms Early - onset seizures, cognitive and sensory impairment, & psychiatric and behavioral disorders. Seizures last from days to weeks; sensitive to fever Pre
Slide 28: Seizure Reduction in PCDH19-RE Phase 2 Trial in Patients with Low Allo Levels
©2020 Marinus Pharmaceuticals. All Rights Reserved I Seizure Reduction in PCDH19 - RE Phase 2 Trial in Patients with Low Allo Levels • 25% decrease in median seizure frequency reported in Phase 2 (n=11) • Stratification of patients by baseline plasma Allo levels identifies a subpopulation with expec
Slide 29: Biomarker Stratified Proof of Concept Study in PCDH19
©2020 Marinus Pharmaceuticals. All Rights Reserved I Biomarker Stratified Proof of Concept (POC) Study in PCDH19 29 Trial Details • Ages 1 - 17 with 8 or more seizures in 8 weeks, failed 2 or more AEDs • Expect to complete double - blind portion of the trial with ~15 - 20 patients • Stratify patient
Slide 30: Intellectual Property
Intellectual Property
Slide 31: Multiple Layers Of Potential Protection
©2020 Marinus Pharmaceuticals. All Rights Reserved I Patent Expected Patent Life Synthesis patents issued in US, Australia, China, Europe, Japan, Mexico & New Zealand 2030 IV formulations containing exclusively in - licensed proprietary Captisol ® product 2033 SE – pending patent on IV formulations
Slide 32: Thank You
Thank You
Slide 33: Appendix: Details on Baseline Characteristics for SE Patients
©2020 Marinus Pharmaceuticals. All Rights Reserved I Appendix 33 NCSE: Non - convulsive status epilepticus CSE: Convulsive status epilepticus LAC: Lacosamide LEV: Levetiracetam LOR: Lorazepam PHT: Phenytoin fPHT : Fosphenytoin VPA: Valproic Acid Details on Baseline Characteristics for SE Patients *B
Marinus Pharmaceuticals — Investor Presentation (May 2020) on 6ix